Correlation Engine 2.0
Clear Search sequence regions


  • cai (1)
  • cancer (6)
  • CD200 (1)
  • CD276 (1)
  • CD28 (1)
  • CD70 (1)
  • CSMD3 (1)
  • diagnosis (1)
  • DNAH5 (1)
  • erlotinib (1)
  • expressed genes (1)
  • gefitinib (1)
  • METTL14 (1)
  • MUC4 (1)
  • NRP1 (1)
  • paclitaxel (1)
  • patients (2)
  • poor prognosis (1)
  • prognostic (7)
  • Ras (8)
  • RBM15 (1)
  • squamous cell carcinoma (2)
  • TNFRSF8 (1)
  • TNFRSF9 (1)
  • TNFSF4 (1)
  • tumour (1)
  • YTHDF3 (1)
  • ZC3H13 (1)
  • ZNF804B (1)
  • Sizes of these terms reflect their relevance to your search.

    Oesophageal squamous cell carcinoma (ESCC) remains a clinically challenging disease with high morbidity rates and poor prognosis. ESCC is also the most common pathological type of oesophageal cancer (EC) in China. Ras-related genes are one of the most frequently mutated gene families in cancer and regulate tumour development and progression. Given this, we investigated the Ras-related gene expression profiles and their values in ESCC prognosis, using data from the Genotype-Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) databases. We found that we could identify three distinct oesophageal cancer clusters based on their unique expression profile for 11 differentially expressed Ras-related genes with each of these demonstrating some prognostic value when, evaluated using univariate Cox analysis. We then used multivariate Cox analysis to identify relevant independent prognostic indicators and used these to build a new prognostic prediction model for oesophageal cancer patients using these three Ras-related genes. These evaluations produced an area under the curve (AUC) of 0.932. We found that our Ras-related signatures could also act as independent factors in ESCC prognosis and that patients with low Ras scores showed a higher overall expression levels of various immune checkpoint genes, including TNFSF4, TNFRSF8, TNFRSF9, NRP1, CD28, CD70, CD200, CD276, METTL16, METTL14, ZC3H13, YTHDF3, VIRMA, FTO, and RBM15, as well as a higher CSMD3, FLG, DNAH5, MUC4, PLCO, EYS, and ZNF804B mutation rates, and better sensitivity to drugs such as erlotinib, paclitaxel, and gefitinib. In conclusion, we were able to use the unique expression profiles of several Ras-related genes to produce a novel disease signature which might facilitate improved prognosis in ESCC, providing new insight into both diagnosis and treatment in these cancers. Copyright © 2022 Yang, Liu, Zheng, Cai, Luo, Feng and Lei.

    Citation

    Hao-Shuai Yang, Wei Liu, Shao-Yi Zheng, He-Yuan Cai, Hong-He Luo, Yan-Fen Feng, Yi-Yan Lei. A Novel Ras--Related Signature Improves Prognostic Capacity in Oesophageal Squamous Cell Carcinoma. Frontiers in genetics. 2022;13:822966


    PMID: 35281814

    View Full Text